GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
This email address is being protected from spambots. You need JavaScript enabled to view it.
Julia Weilman
Burns McClellan
Phone: 646-732-4443
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$8.05 |
Daily Change: | 0.58 7.76 |
Daily Volume: | 4,686,277 |
Market Cap: | US$572.110M |
November 12, 2024 November 07, 2024 October 15, 2024 September 30, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB